VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Plant Produced AHSV VP2 vaccine
Vaccine Information
  • Vaccine Name: Plant Produced AHSV VP2 vaccine
  • Target Pathogen: African horse sickness virus
  • Type: Subunit vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Antigen: VP2 (O'Kennedy et al., 2022)
  • VP2 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Preparation: AHSV-5 VP2 was produced in N. benthamiana DXT/FT. D-(+)-Trehalose dihydrate (Sigma-Aldrich)(5 % m/v) was added to the IMAC purified VP2 antigens before filter sterilization with a 0.45 lM + 0.2 lM Sartopore 2 sterile capsule (Sartorius, 5441307H4) using a peristaltic pump. The appropriate filter sterilised VP2 antigens were mixed with autoclaved adjuvant (5% Montanide GEL 01 PR, Seppic, France) immediately before vaccination. (O'Kennedy et al., 2022)
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Description: A plant produced AHSV Vaccine expressing VP2 antigen protects against AHSV-5 challenge in mice. (O'Kennedy et al., 2022)
Host Response

Mouse Response

  • Vaccination Protocol: Eight groups of IFNAR-/- mice (n = 3) were vaccinated intraperitoneally with 1 µg, 5 µg or 10 µg plant-produced VLPs or VP2. Five groups of mice (n = 6 for vaccinated; and n = 3 for control groups) were used in the challenge study. Mice in the challenge study, were prime boost vaccinated (days 0 and 14) with either 10 µg VLPs (group 1) or 10 µg VP2 (group 2) or PBS buffer (negative control, group 3) or BEI inactivated 5x104 PFU (positive control, group 4). (O'Kennedy et al., 2022)
  • Immune Response: Mice vaccinated with a single dose of plant-produced chimaeric AHSV- 1/5 VLPs seroconverted at a 5 µg and 10 µg vaccine dose, within the first 14 days. The primary vaccination of AHSV-1/5 VLPs led to seroconversion of 1:40 (1.6 log10) and 1:28 (1.45 log10) when vaccinated with 5 and 10 lg AHSV-1/5 VLPs already on day 14, respectively. A booster vaccine was however necessary to elevate the neutralizing antibodies (nAbs) to 1:320 (2.5 log10) on day 28 for all VLP vaccine doses. Ten micrograms of soluble VP2 per mouse were required to equal this immune response after prime-boost vaccination. All the test antigens indicated a measure of CD4+/ CD8+ stimulation which is required to induce cell memory. Mice vaccinated with plant-produced AHSV-1/5 VLPs showed a larger increase in stimulation as compared to the OBP BEI inactivated vaccine as positive control and to a lesser extent for the soluble VP2 vaccinated mice. (O'Kennedy et al., 2022)
  • Challenge Protocol: Groups 1–4 were challenged 28 days after the primary vaccine. Challenge with a dose containing 1.4 X 105 pfu of AHSV-5 per mouse on day 28 (14 days post booster immunization) was administered subcutaneously. (O'Kennedy et al., 2022)
  • Efficacy: Protection against AHSV-5 conferred by both plant-produced adjuvanted VLPs and VP2 vaccines correlated strongly with SNTs determined during the immunogenicity study and mice (n = 6) of each group survived until day 25 post challenge when the study was terminated. The negative control group (PBS with adjuvant) succumbed within 8– 11 days after challenge. (O'Kennedy et al., 2022)
References